Lessons from the GHOST-EU registry.
Bifurcations are increasingly being treated with bioresorbable vascular scaffolds (BVS) and accounted for about 25% of patients treated in the large multicentre GHOST-EU registry. This registry, along with bench testing, has provided a glimpse of the techniques and limitations of treating bifurcations with BVS. The provisional strategy remains the default approach to bifurcation treatment with BVS. If correctly performed, SB dilatation, T-kissing inflation, crossover to side branch stenting and elective double stenting are feasible without causing scaffold disruption. Theoretically, when the scaffolds are resorbed, the normal bifurcation anatomy, flow and vascular function will be restored, while jailed SBs will be liberated. However, data from the GHOST-EU registry are awaited to confirm the long-term safety and efficacy of BVS in coronary bifurcations.